Paxlovid

DRUG12 trials

Conditions

AzvudineBiological AvailabilityCOVID - 19COVID-19COVID-19 PneumoniaCovid19Healthy ParticipantsLong COVID

Early Phase 1

Paxlovid in the Treatment of COVID-19 Patients With Uremia

NCT05386433

Ruijin HospitalCOVID-19, Uremia

Start: 2022-06-30End: 2022-08-31Target: 40Updated: 2022-05-23

Phase 1

AGILE (Early Phase Platform Trial for COVID-19)

RecruitingNCT04746183

University of LiverpoolCovid19

Start: 2020-07-03End: 2026-07-31Target: 600Updated: 2026-01-14

A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants

WithdrawnNCT06397144

PfizerBiological Availability, Healthy Participants

Start: 2025-08-15End: 2025-12-09Updated: 2025-12-26

Phase 2

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms

CompletedNCT05965726

Kanecia Obie ZimmermanLong COVID, Long COVID-19

Start: 2023-07-26End: 2025-03-13Updated: 2026-03-27

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

RecruitingNCT07157007

Traws Pharma, Inc.COVID - 19

Start: 2025-09-16End: 2026-03-01Target: 90Updated: 2026-01-21

Phase 3

Randomised Evaluation of COVID-19 Therapy

RecruitingNCT04381936

University of OxfordSevere Acute Respiratory Syndrome

Start: 2020-03-19End: 2036-06-30Target: 70000Updated: 2024-01-05

Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

CompletedNCT05341609

Vigonvita Life SciencesCOVID-19

Start: 2022-04-04End: 2022-05-31Updated: 2022-09-21

Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings

Active, not recruitingNCT05614349

Unity Health TorontoCOVID-19

Start: 2023-01-16End: 2025-06-28Updated: 2025-05-16

UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients

NCT05682586

Shanghai East HospitalCOVID-19 Pneumonia, Mesenchymal Stem Cell

Start: 2023-01-09End: 2023-07-01Target: 60Updated: 2023-01-12

Unknown Phase

A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19

RecruitingNCT05387369

Huashan HospitalCOVID-19

Start: 2022-03-21End: 2027-03-30Target: 2000Updated: 2022-05-24

A Registry Study of Patients Hospitalized With Confirmed COVID-19

NCT05792865

Beijing Chao Yang HospitalCOVID-19

Start: 2023-03-30End: 2023-12-30Target: 488Updated: 2023-03-31

A Registry Study of Patients Hospitalized With Confirmed COVID-19

NCT05792865

Beijing Chao Yang HospitalCOVID-19

Start: 2023-03-30End: 2023-12-30Target: 488Updated: 2023-03-31

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

CompletedNCT06349655

The First Affiliated Hospital of Zhengzhou UniversityAzvudine, COVID-19

Start: 2023-12-05End: 2024-03-10Updated: 2024-04-05

2026-03-18

Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID): recruitment strategies of a decentralized, national randomized controlled trial for acute SARS-CoV-2

Frontiers in Public Health2026-02-11

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2025-08-282 citations

Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings

BMJ Open2025-08-01

Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China

BMJ Open2025-06-01

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases.

2025-05-19

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2025-05-151 citations

The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study

View2025-04-09

The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study

Advanced Science2025-02-22

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

2025-02-124 citations

Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study

View2025-02-05

Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study.

2024-11-172 citations

Optimal dose and safety of intravenous favipiravir in hospitalized patients with SARS‐COV‐2: A phase I, open‐label, dose‐escalating, randomized controlled study

British Journal of Clinical Pharmacology2024-09-01

Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza.

2024-08-016 citations

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England

Trials2024-06-294 citations

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2024-01-317 citations

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

2024-01-2218 citations

Dapagliflozin in patients with critical illness: rationale and design of the DEFENDER study.

2023-12-222 citations

Cardiac assessment and inflammatory markers in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV2 (PIMS-TS) treated with methylprednisolone versus intravenous immunoglobulins: 6-month follow-up outcomes of the randomised controlled Swissped RECOVERY trial.

2023-12-065 citations

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2023-10-1823 citations

35 more papers not shown